OnabotulinumtoxinA not only reduces anxiety, fatigue and depression but also reduces headache frequency and improve symptoms of poor sleep quality, as per the information gained by a recent open-label, prospective, multicentre analysis of the Journal of Neurology, Neurosurgery, and Psychiatry.

A total of nine treatments were given to patients with chronic migraine (CM) under the Chronic Migraine OnabotulinumtoxinA Prolonged Efficacy open-Label (COMPEL) study. Efficacy of OnabotulinumtoxinA on depression and anxiety assessed by applying the Generalised Anxiety Disorder (GAD-7) and The Patient Health Questionnaire (PHQ-9) scales, respectively and clinical improvement by the percentage of participants enduring a ≥1 severity category decrease in GAD-7 and PHQ-9. The Fatigue Severity Scale and the Pittsburgh Sleep Quality Index were used to measure the association of onabotulinumtoxinA with fatigue and sleep quality.

A sustained decline in PHQ-9, GAD-7 scores and headache days were noticed with OnabotulinumtoxinA treatment over 108 weeks. GAD-7 and PHQ-9 scores were considerably decreased at all time points among participants with clinically notable signs of anxiety and/or depression at baseline. Fatigue and sleep quality were also improved, although, limited is known regarding clinically important changes in these measures. No adverse effects were noticed during the analysis. These findings demonstrated Onabotulinumtoxin A as an important treatment regimen for chronic migraine.